{"id":"active-jnj-54175446","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_fixedAt":"2026-03-30T14:28:09.023200","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, JNJ-54175446 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"JNJ-54175446 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:19:00.610Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"_fixedFields":["pubmed(7)"],"trialDetails":[{"nctId":"NCT04116606","phase":"PHASE2","title":"Antidepressant Trial With P2X7 Antagonist JNJ-54175446","status":"UNKNOWN","sponsor":"CCTU-Core","startDate":"2019-09-12","conditions":"Depressive Disorder, Major, Inflammation","enrollment":142},{"nctId":"NCT03058419","phase":"PHASE1","title":"A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-03-14","conditions":"Healthy","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"recentPublications":[{"date":"2025 Jul 15","pmid":"40673252","title":"Continuous-flow synthesis of 1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridines towards key intermediates of clinical candidates JNJ-54175446 and zanvipixant (JNJ-55308942) with antidepressant activity.","journal":"RSC advances"},{"date":"2021 Jun","pmid":"33728582","title":"Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer.","journal":"Purinergic signalling"},{"date":"2021 May","pmid":"33130128","title":"Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets.","journal":"Biochemical pharmacology"},{"date":"2020 Sep","pmid":"32248747","title":"Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.","journal":"Journal of psychopharmacology (Oxford, England)"},{"date":"2019 Aug","pmid":"30733317","title":"Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of (18)F-JNJ-64413739, a PET Radioligand for P2X7 Receptors.","journal":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Active JNJ-54175446","genericName":"Active JNJ-54175446","companyName":"CCTU-Core","companyId":"cctu-core","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JNJ-54175446 is being studied in a clinical trial for its effects on depressive disorder, major, inflammation, and in healthy individuals. The study involves administering JNJ-54175446 at doses of 150 mg and 600 mg, as well as midazolam 2 mg, to evaluate its effects.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}